Resonant Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.63M Buy
6,123
+410
+7% +$416K 0.3% 60
2025
Q4
$6.14M Buy
5,713
+161
+3% +$154K 0.34% 55
2025
Q3
$4.24M Sell
5,552
-292
-5% -$217K 0.25% 70
2025
Q2
$4.56M Buy
5,844
+561
+11% +$436K 0.29% 68
2025
Q1
$4.36M Buy
5,283
+287
+6% +$239K 0.3% 66
2024
Q4
$3.86M Buy
4,996
+69
+1% +$57.1K 0.28% 73
2024
Q3
$4.37M Sell
4,927
-574
-10% -$516K 0.32% 65
2024
Q2
$4.98M Buy
5,501
+142
+3% +$114K 0.4% 54
2024
Q1
$4.17M Buy
5,359
+747
+16% +$532K 0.36% 59
2023
Q4
$2.69M Sell
4,612
-256
-5% -$149K 0.26% 80
2023
Q3
$2.61M Sell
4,868
-102
-2% -$52.6K 0.28% 80
2023
Q2
$2.33M Buy
4,970
+182
+4% +$76.3K 0.25% 88
2023
Q1
$1.64M Buy
4,788
+35
+0.7% +$11.8K 0.19% 105
2022
Q4
$1.74M Sell
4,753
-106
-2% -$37.6K 0.22% 99
2022
Q3
$1.57M Buy
4,859
+1,916
+65% +$607K 0.24% 91
2022
Q2
$954K Buy
2,943
+436
+17% +$131K 0.15% 107
2022
Q1
$734K Buy
2,507
+149
+6% +$38.3K 0.11% 113
2021
Q4
$651K Buy
2,358
+222
+10% +$56.3K 0.1% 117
2021
Q3
$494K Buy
2,136
+45
+2% +$11.1K 0.09% 127
2021
Q2
$480K Buy
2,091
+21
+1% +$4.22K 0.09% 116
2021
Q1
$387K Hold
2,070
0.08% 130
2020
Q4
$349K Sell
2,070
-150
-7% -$22.4K 0.08% 138
2020
Q3
$329K Sell
2,220
-133
-6% -$20.6K 0.09% 122
2020
Q2
$386K Hold
2,353
0.11% 124
2020
Q1
$326K Sell
2,353
-1,655
-41% -$227K 0.12% 153
2019
Q4
$527K Buy
+4,008
New +$465K 0.17% 142

Other funds holding LLY

Resonant Capital Advisors's LLY Position: Q1 2026 in Review

Resonant Capital Advisors increased its Eli Lilly (LLY) stake by 7.2% in Q1 2026, buying an estimated $416K and bringing the position to 6,123 shares worth $5.63M. The position accounts for 0.3% of the portfolio, ranked #60.

Resonant Capital Advisors first reported a position in LLY in Q4 2019 and has held it in 26 quarters since. The position peaked at $6.14M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Resonant Capital Advisors held 6,123 shares of Eli Lilly worth $5.63M as of Q1 2026.
  • Resonant Capital Advisors bought 410 Eli Lilly shares in Q1 2026, an estimated $416K.
  • Eli Lilly made up 0.3% of Resonant Capital Advisors's portfolio in Q1 2026, its #60 holding.
  • Resonant Capital Advisors first reported a position in Eli Lilly in Q4 2019 and has held it in 26 quarters since.
  • Resonant Capital Advisors's Eli Lilly position peaked at $6.14M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Resonant Capital Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.